We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Programming CAR T Cells so That They Only Kill Cancer Cells
News

Programming CAR T Cells so That They Only Kill Cancer Cells

Programming CAR T Cells so That They Only Kill Cancer Cells
News

Programming CAR T Cells so That They Only Kill Cancer Cells

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Programming CAR T Cells so That They Only Kill Cancer Cells"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A study recently published in the journal Science looked into how CAR T immunotherapy could be used to treat solid tumours in addition to leukaemias. The programming of CAR T cells opens avenues for applying cell therapies to, for example, breast cancer or ovarian cancer in the future.

In cancer immunotherapy, cells in the patient’s own immune system are activated to attack cancer cells. CAR T cell therapy has been one of the most significant recent advances in immunotherapies targeted at cancer.


In CAR T cell therapy, T cells are extracted from the patient for genetic modification: a chimeric antigen receptor (CAR) is transported into the cells using a viral vector, helping the T cells better identify and kill cancer cells. When the antigen receptor cells identify the desired surface structure in the patient’s cells, they start multiplying and killing the target cells.



Teach Me in 10: CAR T Cells: A Living Targeted Drug, With Dr Matt Cooper.

CAR T cell therapy was introduced to Finland in 2018, and the treatment form has been used in support of patients suffering from leukaemia and lymphomas.

So far, the application of CAR T cell therapy to solid tumours has been difficult: targeting the therapy at just the tumour is difficult when the cancer type is not associated with any specific surface structure. In many cancer types, there is an abundance of a specific protein on the tumour’s surface, but as the protein also occurs in low numbers in normal tissue, CAR T cell therapy is not able to discriminate between target protein levels. This is why genetically modified cells are quick to attack also healthy cells and organs, which can result in fatal adverse effects associated with the treatment.

A study recently published in the Science journal has found a solution to applying CAR T cell therapy to solid tumours as well: through collaboration, American and Finnish researchers identified a new way of programming CAR T cells so that they only kill cancer cells, leaving alone healthy cells that have the same marker protein as cancer cells.

New tech­nique based on ul­tra­sens­it­ive iden­ti­fic­a­tion of HER2 cells, fur­ther
in­vest­ig­a­tion un­der­way

HER2 is a protein characteristic of, among others, breast cancer, ovarian cancer and abdominal cancers. The protein can also occur in great numbers on the surface of tumour cells, since, as a result of gene amplification, HER2 expression can be multiplied in tumours.

A new CAR T cell engineering technique developed by the researchers is based on a two-step identification process of HER2 positive cells. Thanks to the engineering, the researchers were able to produce a response where CAR T cells kill only the cancer cells in the cancer tissue.

“Our solution requires the preliminary identification of the surface structures associated with the cancer. When the preliminary recognition ability that induces the CAR construct is adjusted to require a binding affinity that is different from the affinity used by CAR to direct the killing of these cells, an extremely accurate ability to differentiate between cells based on the amount of target protein on their surface can be programmed in this two-step ‘circuit’ which controls the function of killer T cells," says Professor of Virology Kalle Saksela from the University of Helsinki.

Further studies for the application of the technique are already ongoing. Postdoctoral Researcher Anna Mäkelä, who works at Professor Saksela’s laboratory, is coordinating a project funded by the Academy of Finland investigating the use of CAR T cell therapy on various cancer types and their surface structures.

“We are very excited about these results, and we are currently developing the technique so that it could be used to treat ovarian cancer. As the work progresses, the aim is to apply the technique itself and the targeting molecules of CAR constructs even more broadly to malignant solid tumours. Our goal is to develop ‘multi-warhead missiles’, against which cancer cells will find it difficult to develop resistance,” Mäkelä says.

Reference: Hernandez-Lopez RA, Yu W, Cabral KA, et al. T cell circuits that sense antigen density with an ultrasensitive threshold. Science. 2021;371(6534):1166. doi:10.1126/science.abc1855.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement